Artificial intelligence (AI) is reshaping industries, with healthcare among those poised for significant transformation. Generative AI is expected to revolutionize drug discovery and clinical trial design processes, with over 500 AI-enabled FDA-approved medical devices sold domestically. In fact, Goldman Sachs (GS) predicts AI-driven healthcare advancements will boost U.S. GDP by 1.3%.
Biotech stock Recursion Pharmaceuticals, Inc. (RXRX) leads on AI-driven drug discovery. Its shares are up over 11% year to date, and have hit several new highs recently.
